Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple MyelomaJesús F. San Miguel, Hermann Einsele, Michèle Cavo et al.|New England Journal of Medicine|2023Cited by 719
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working GroupPhilippe Moreau, Jean‐Luc Harousseau, Shaji Kumar et al.|The Lancet Oncology|2021Cited by 266
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim resultsSham Mailankody, Shaji Kumar, Jeffrey Matous et al.|Nature Medicine|2023Cited by 239
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucelSaurabh Zanwar, Doris K. Hansen, Surbhi Sidana et al.|Journal of Hematology & Oncology|2024Cited by 46
Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal StudyRachel Cusatis, Surbhi Sidana, Irena Tan et al.|Blood|2021Cited by 19